Cannabis compounds CBGA and CBDA have been found to bind to the spike protein of SARS-CoV-2, potentially reducing the risk of coronavirus infection. Researchers at Oregon State University discovered that these compounds, which are abundant and readily available in hemp and hemp extracts, could also help alleviate symptoms of COVID-19. Unlike THC, CBGA and CBDA are not psychoactive and have been shown to be safe and well-tolerated. The compounds can be taken orally and may reduce the risk of infection as well as alleviate symptoms of acute COVID-19. However, the researchers emphasize that the cannabinoids should be used in combination with vaccination and other preventive measures.
The study, published in the Journal of Natural Products, found that CBGA and CBDA bind to the spike protein that the virus uses to enter human cells. The compounds appear to reduce the risk of infection by preventing the virus from entering cells. The researchers also found that the compounds were effective against the Alpha and Beta variants of the virus, and they are optimistic that the compounds will be effective against other variants as well.
The researchers note that while CBGA and CBDA may be helpful in reducing the risk of COVID-19, they are not a substitute for vaccination and other preventive measures. The compounds should be used in combination with vaccination and other preventive measures to reduce the risk of infection and alleviate symptoms of acute COVID-19. The researchers hope that their findings will lead to further research on the potential benefits of cannabis compounds in the prevention and treatment of COVID-19.
